Helpdesk

Sales contact

Home > Resources > Insights from Kayentis clients: why you should choose Kayentis as your eCOA & DCT provider

Insights from Kayentis clients: why you should choose Kayentis as your eCOA & DCT provider

Last updated: July 3, 2024

Responsiveness, reliability, professionalism, friendliness… discover why 95.6% of Kayentis clients recommend Kayentis in 2023!

Challenge your eCOA & DCT provider: choose Kayentis for your next clinical trial!

Subscribe to our newsletter

Engage patients throughout the clinical trial journey

Kayentis accelerates US growth with 40% surge in bookings over...

Empowering patients through education – A structured approach to clinical...

Kayentis introduces its Patient Education Video Library to strengthen clinical...

Expanding investor confidence: The strategic value of Patient Reported Outcomes...

Leveraging the potential of Patient Reported Outcome (PRO) data to...

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

Rethinking Phase 1 Oncology Trials with Electronic Patient-Reported Outcomes

November 4 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET

Oncology, PRO

The primary aim of Phase 1 oncology clinical trials is to determine the safety of a new treatment, and to...